Abstract
Objective
To compare comprehensiveness and accuracy of drug interaction information in the German summary of product characteristics (SPC) with current evidence from the literature and to evaluate the SPC’s usefulness with respect to management of drug interactions.
Methods
Information on clinically relevant drug interactions was compared between the SPC and three standard information sources on drug interactions (DRUGDEX, Hansten/Horn’s Drug Interactions Analysis and Management, Stockley’s Drug Interactions) according to five consecutive criteria (inclusion, appropriateness of class labelling, effect description, management recommendation, explicit dose adjustment). Using medication data of an outpatient population (n=4,949), we determined what percentage of insufficiently characterized combinations indeed occurred in outpatients treated with combination drug therapy.
Results
Only for 33% (192/579) of the evaluated combinations did SPCs provide drug interaction information equivalent to the evidence from the published literature. Of the clinically relevant drug interactions, 16% were completely missing and 51% were insufficiently characterized compared with standard sources. Explicit management recommendations were either missing or differed from standard sources in 18% of the evaluated pairs of compounds. Of these missing or insufficiently characterized combinations, 12% (47/387) were indeed prescribed to outpatients. Those drug combinations for which the interaction potential was not mentioned in the SPC were received by 0.6% (32/4,949) of patients, and 4% (192/4,949) of patients received combinations that had insufficiently characterized drug interactions.
Conclusions
If physicians only rely on SPC information for drug interactions, adverse events due to lacking management recommendations may occur. To meet the SPCs claim of being the basis of information for health professionals on how to use medicinal products safely and effectively, information on drug interactions should be thoroughly up-dated and expanded.
Similar content being viewed by others
References
Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboom-de Jong B (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261–267
Rosholm JU, Bjerrum L, Hallas J, Worm J, Gram LF (1998) Polypharmacy and the risk of drug-drug interactions among Danish elderly. Dan Med Bull 45:210–213
Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76:85–96
Bergk V, Gasse C, Schnell R, Haefeli WE (2004) Requirements for a successful implementation of drug interaction information systems in general practice: results of a questionnaire survey in Germany. Eur J Clin Pharmacol 60:595–602
Rawlins MD (1996) The clinical pharmacologist in drug regulation: a European perspective. Br J Clin Pharmacol 42:59–61
Rajpal A, Reidenberg MM (2003) Drug labeling should be kept current. Clin Pharmacol Ther 73:4–6
Mullen WH, Anderson IB, Kim SY, Blanc PD, Olson KR (1997) Incorrect overdose management advice in the Physicians’ Desk Reference. Ann Emerg Med 29:255–261
Spyker DA, Harvey ED, Harvey BE, Harvey AM, Rumack BH, Peck CC, Atkinson AJ Jr, Woosley RL, Abernethy DR, Cantilena LR (2000) Assessment and reporting of clinical pharmacology information in drug labeling. Clin Pharmacol Ther 67:196–200
Cohen JS (2001) Dose discrepancies between the Physicians’ Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 161:957–964
European Commission (2004) Notice to applicants. A guideline on summary of product characteristics (EC). Available from: URL:http://pharmacos.eudra.org/F2/eudralex/vol-2/C/SPCGuidRev0-Dec99.pdf. Accessed May 19, 2004
Marroum PJ, Gobburu J (2002) The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet 41:161–169
Aronson JK (2004) Drug interactions—information, education, and the British National Formulary. Br J Clin Pharmacol 57:371–372
Anonymous (2001) Failings in treatment advice, SPCs and black triangles. Drug Ther Bull 39:25–27
Martin-Facklam M, Rengelshausen J, Tayrouz Y, Ketabi-Kiyanvash N, Lindenmaier H, Schneider V, Bergk V, Haefeli WE (2005) Dose individualisation in patients with renal insufficiency: does drug labelling support optimal management? Eur J Clin Pharmacol 60:807–811
Klasko RK (ed) (2003) DRUGDEX System. MICROMEDEX Inc. Greenwood Village, Colorado, version used: first quarter 2003
Stockley IH (2002) Stockley’s drug interactions. The Pharmaceutical Press, London
Hansten PD, Horn JR (2003) Drug interactions analysis and management. Facts and Comparisons, St. Louis
Fachinformationsverzeichnis Deutschland (einschließlich EU-Zulassungen) (2003) BPI Service GmbH, Frankfurt, Germany, version used: first quarter 2003
Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB (1999) The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol 39:86–90
Pan HY (1991) Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 40[Suppl 1]:S15–S18
McColl A, Smith H, White P, Field J (1998) General practitioner’s perceptions of the route to evidence based medicine: a questionnaire survey. BMJ 316:361–365
Prosser H, Almond S, Walley T (2003) Influences on GPs’ decision to prescribe new drugs-the importance of who says what. Fam Pract 20:61–68
Sjöqvist F (1997) A new classification system for drug interactions. Eur J Clin Pharmacol 52[Suppl 1]:A126
Fachinformationsverzeichnis Deutschland (einschließlich EU-Zulassungen).(2004) BPI Service GmbH, Frankfurt, Germany. Available from: URL:http://www.fachinfo.de. Accessed December 15, 2004
Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, Kopp C, Montane E, Rago L, Rocchi F; The International Comparative Study on Drug Information Collaborative Group (2003) Prescribing information in 26 countries: a comparative study. Eur J Clin Pharmacol 59:263–270
McInnes GT, Brodie MJ (1988) Drug interactions that matter. A critical reappraisal. Drugs 36:83–110
Acknowledgements
This research was supported in part by the Graduiertenkolleg 793 (German Research Foundation, DFG).
Conflict of interest:
No information supplied
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bergk, V., Haefeli, W.E., Gasse, C. et al. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 61, 327–335 (2005). https://doi.org/10.1007/s00228-005-0943-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0943-4